Ramona Doyle - 31 Jan 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Medical Officer
Signature: /s/ Nathan Hatfield, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 31 Jan 2022
Net transactions value: +$38,750
Form type: 4
Filing time: 02 Feb 2022, 19:11:45 UTC
Previous filing: 05 Jan 2022
Next filing: 08 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Options Exercise	$38,750	+15,625	+37%	$2.48	57,335	31 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-15,625	-2.2%	$0.000000	694,053	31 Jan 2022	Class A Common Stock	15,625	$2.48	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2	Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021
F3	Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.